Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Axsome Therapeutics Inc (NASDAQ: AXSM) was $71.17 for the day, down -2.61% from the previous closing price of $73.08. In other words, the price has decreased by -$2.61 from its previous closing price. On the day, 0.58 million shares were traded. AXSM stock price reached its highest trading level at $73.14 during the session, while it also had its lowest trading level at $69.92.
Ratios:
Our analysis of AXSM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.52 and its Current Ratio is at 3.63. In the meantime, Its Debt-to-Equity ratio is 0.98 whereas as Long-Term Debt/Eq ratio is at 0.97.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on March 19, 2024, initiated with a Outperform rating and assigned the stock a target price of $108.
On February 06, 2024, UBS started tracking the stock assigning a Buy rating and target price of $111.
On January 25, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $126.RBC Capital Mkts initiated its Outperform rating on January 25, 2024, with a $126 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 01 ’24 when Jacobson Mark L. sold 24,662 shares for $77.24 per share. The transaction valued at 1,904,942 led to the insider holds 0 shares of the business.
JEFFS ROGER sold 2,347 shares of AXSM for $168,062 on Mar 15 ’24. The Director now owns 120,756 shares after completing the transaction at $71.61 per share. On Mar 14 ’24, another insider, JEFFS ROGER, who serves as the Director of the company, sold 29,976 shares for $69.70 each. As a result, the insider received 2,089,387 and left with 120,756 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 3371635968 and an Enterprise Value of 3171813376. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.46 while its Price-to-Book (P/B) ratio in mrq is 17.65. Its current Enterprise Value per Revenue stands at 11.721 whereas that against EBITDA is -17.385.
Stock Price History:
Over the past 52 weeks, AXSM has reached a high of $98.40, while it has fallen to a 52-week low of $55.02. The 50-Day Moving Average of the stock is -7.50%, while the 200-Day Moving Average is calculated to be -4.87%.
Shares Statistics:
AXSM traded an average of 733.12K shares per day over the past three months and 618560 shares per day over the past ten days. A total of 47.35M shares are outstanding, with a floating share count of 38.78M. Insiders hold about 18.14% of the company’s shares, while institutions hold 80.87% stake in the company. Shares short for AXSM as of 1711584000 were 7650712 with a Short Ratio of 10.44, compared to 1709164800 on 7470339. Therefore, it implies a Short% of Shares Outstanding of 7650712 and a Short% of Float of 19.440001000000002.
Earnings Estimates
The performance of Axsome Therapeutics Inc (AXSM) in the stock market is under the watchful eye of 14.0 analysts actively contributing to its current rating.On average, analysts expect EPS of -$1.18 for the current quarter, with a high estimate of -$0.94 and a low estimate of -$1.45, while EPS last year was -$0.26. The consensus estimate for the next quarter is -$1.0, with high estimates of -$0.7 and low estimates of -$1.26.
Analysts are recommending an EPS of between -$1.85 and -$5.02 for the fiscal current year, implying an average EPS of -$3.77. EPS for the following year is $1.13, with 12.0 analysts recommending between $4.9 and -$2.51.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 14 analysts. It ranges from a high estimate of $88M to a low estimate of $65.7M. As of the current estimate, Axsome Therapeutics Inc’s year-ago sales were $26.07MFor the next quarter, 14 analysts are estimating revenue of $88.89M. There is a high estimate of $101M for the next quarter, whereas the lowest estimate is $80.5M.
A total of 16 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $450.08M, while the lowest revenue estimate was $339.58M, resulting in an average revenue estimate of $378.24M. In the same quarter a year ago, actual revenue was $270.6MBased on 15 analysts’ estimates, the company’s revenue will be $698M in the next fiscal year. The high estimate is $942.55M and the low estimate is $538.95M.
